Chandra Bhagat Pharma Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 11, 2025, 11:36 pm

Market Cap	48.9 Cr.
Current Price	64.8
High / Low	124/55.4
Stock P/E	30.9
Book Value	39.4
Dividend Yield	0.00 %
ROCE	7.95 %
ROE	5.42 %
Face Value	10.0
PEG Ratio	0.58

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Chandra Bhagat Pharma Ltd

Competitors of Chandra Bhagat Pharma Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	6.71 Cr.	3.51	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	53.1 Cr.	71.5	94.9/32.1	18.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	38.0 Cr.	26.0	29.0/8.74	38.8	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	70.4 Cr.	93.5	155/79.0	11.4	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,255.37 Cr	1,081.84		42.42	185.80	0.37%	16.00%	16.32%	6.27

All Competitor Stocks of Chandra Bhagat Pharma Ltd

Quarterly Result

Metric	Sep 2020	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024
Sales	22	48	43	51	44	75	119	102	65
Expenses	21	47	42	50	43	74	124	104	66
Operating Profit	2	2	2	1	1	2	-5	-2	-1
OPM %	7%	3%	4%	2%	2%	2%	-4%	-2%	-2%
Other Income	0	0	0	1	1	0	7	4	3
Interest	2	2	1	2	1	1	1	1	1
Depreciation	0	0	0	0	0	0	0	0	0
Profit before tax	0	0	1	1	1	1	1	1	1
Tax %	25%	33%	24%	31%	31%	15%	32%	34%	-11%
Net Profit	0	0	0	0	0	1	1	1	1
EPS in Rs	0.04	0.21	0.57	0.48	0.49	0.72	0.83	1.19	0.90

Last Updated: January 5, 2025, 8:27 am

Below is a detailed analysis of the quarterly data for Chandra Bhagat Pharma Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Sales, as of Sep 2024, the value is ₹65.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Mar 2024) to ₹65.00 Cr., marking a decrease of 37.00 Cr..
For Expenses, as of Sep 2024, the value is ₹66.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 104.00 Cr. (Mar 2024) to ₹66.00 Cr., marking a decrease of 38.00 Cr..
For Operating Profit, as of Sep 2024, the value is ₹-1.00 Cr.. The value appears strong and on an upward trend. It has increased from -2.00 Cr. (Mar 2024) to ₹-1.00 Cr., marking an increase of ₹1.00 Cr..
For OPM %, as of Sep 2024, the value is -2.00%. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded -2.00%.
For Other Income, as of Sep 2024, the value is ₹3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Mar 2024) to ₹3.00 Cr., marking a decrease of 1.00 Cr..
For Interest, as of Sep 2024, the value is ₹1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
For Depreciation, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Profit before tax, as of Sep 2024, the value is ₹1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
For Tax %, as of Sep 2024, the value is -11.00%. The value appears to be improving (decreasing) as expected. It has decreased from 34.00% (Mar 2024) to -11.00%, marking a decrease of 45.00%.
For Net Profit, as of Sep 2024, the value is ₹1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
For EPS in Rs, as of Sep 2024, the value is 0.90. The value appears to be declining and may need further review. It has decreased from ₹1.19 (Mar 2024) to 0.90, marking a decrease of ₹0.29.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 1:38 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	35	48	61	80	90	97	106	94	71	94	120	221	167
Expenses	35	46	58	76	85	92	102	91	67	91	116	228	170
Operating Profit	0	2	3	3	4	5	5	3	4	3	3	-7	-3
OPM %	1%	4%	5%	4%	5%	5%	4%	3%	5%	3%	3%	-3%	-2%
Other Income	0	1	0	0	0	1	0	0	0	2	0	11	7
Interest	0	2	2	3	4	4	4	3	4	3	2	1	2
Depreciation	0	0	0	0	0	0	0	0	0	0	0	1	1
Profit before tax	0	0	1	1	1	2	1	0	0	1	1	2	2
Tax %	27%	17%	39%	51%	27%	33%	22%	26%	32%	27%	22%	33%
Net Profit	0	0	0	0	1	1	1	0	0	1	1	2	2
EPS in Rs	9.60	8.37	10.29	8.37	15.79	24.64	10.29	0.41	0.25	1.06	1.21	2.03	2.09
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2017-2018	2018-2019	2019-2020	2022-2023	2023-2024
YoY Net Profit Growth (%)	0.00%	0.00%	-100.00%	0.00%	100.00%
Change in YoY Net Profit Growth (%)	0.00%	0.00%	-100.00%	100.00%	100.00%

Chandra Bhagat Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2017-2018 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: November 14, 2024, 5:35 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	0.25	0.42	0.42	0.42	0.42	0.42	0.67	8	8	8	8	8	8
Reserves	3	6	6	6	7	8	14	18	18	19	20	21	22
Borrowings	11	19	28	28	22	22	31	30	27	21	19	16	23
Other Liabilities	9	7	8	10	26	28	37	19	19	25	14	56	42
Total Liabilities	24	32	42	44	56	58	83	75	72	72	61	102	95
Fixed Assets	1	1	1	1	1	1	0	0	0	0	1	3	2
CWIP	0	0	0	0	0	0	0	0	0	0	0	0	0
Investments	0	0	0	0	5	1	4	1	0	0	0	0	1
Other Assets	23	31	41	44	51	56	78	74	71	72	60	99	92
Total Assets	24	32	42	44	56	58	83	75	72	72	61	102	95

Below is a detailed analysis of the balance sheet data for Chandra Bhagat Pharma Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹8.00 Cr..
For Reserves, as of Sep 2024, the value is ₹22.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹21.00 Cr. (Mar 2024) to ₹22.00 Cr., marking an increase of 1.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹23.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from ₹16.00 Cr. (Mar 2024) to ₹23.00 Cr., marking an increase of 7.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹42.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹56.00 Cr. (Mar 2024) to ₹42.00 Cr., marking a decrease of 14.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹95.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹102.00 Cr. (Mar 2024) to ₹95.00 Cr., marking a decrease of 7.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹2.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹3.00 Cr. (Mar 2024) to ₹2.00 Cr., marking a decrease of 1.00 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Investments, as of Sep 2024, the value is ₹1.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹0.00 Cr. (Mar 2024) to ₹1.00 Cr., marking an increase of 1.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹92.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹99.00 Cr. (Mar 2024) to ₹92.00 Cr., marking a decrease of 7.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹95.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹102.00 Cr. (Mar 2024) to ₹95.00 Cr., marking a decrease of 7.00 Cr..

However, the Borrowings (23.00 Cr.) are higher than the Reserves (₹22.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	-0	-0	-0	-0	-9	-6	4	-7	8	12	5	6
Cash from Investing Activity +	-0	-0	-0	-0	0	-0	-0	0	0	0	-0	-2
Cash from Financing Activity +	-0	-0	-0	-0	8	7	-4	7	-6	-10	-4	-6
Net Cash Flow	-0	-0	-0	-0	-1	-0	-0	-0	2	3	1	-1

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-11.00	-17.00	-25.00	-25.00	-18.00	-17.00	-26.00	-27.00	-23.00	-18.00	-16.00	-23.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	85	65	71	66	80	67	90	54	80	58	25	65
Inventory Days		161	177	123	133	145	174	187	215	153	100	15
Days Payable		53	43	33	81	69	117	53	79	12	11	23
Cash Conversion Cycle	85	174	205	156	132	143	146	188	216	199	114	57
Working Capital Days	107	149	166	134	125	138	139	212	258	165	121	61
ROCE %	2%	12%	10%	10%	15%	17%	13%	7%	7%	9%	7%	8%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2020	Sep 2020	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024
Promoters	70.42%	70.42%	71.80%	71.80%	70.11%	69.09%	68.24%	68.69%	68.77%	69.29%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.85%	0.85%	1.33%	1.33%	0.48%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.89%	0.89%	0.00%
Public	29.58%	29.58%	28.20%	28.20%	29.89%	30.07%	30.91%	29.09%	29.02%	30.23%
No. of Shareholders	178	156	106	90	126	126	146	134	152	315

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	2.03	1.20	1.06	0.25	0.55
Diluted EPS (Rs.)	2.03	1.20	1.06	0.25	0.55
Cash EPS (Rs.)	2.88	1.55	1.22	0.29	0.45
Book Value[Excl.RevalReserv]/Share (Rs.)	38.45	36.42	35.35	34.30	34.05
Book Value[Incl.RevalReserv]/Share (Rs.)	38.45	36.42	35.35	34.30	34.05
Revenue From Operations / Share (Rs.)	293.40	158.61	124.68	93.70	124.56
PBDIT / Share (Rs.)	5.69	4.79	5.69	1.05	4.66
PBIT / Share (Rs.)	4.84	4.44	5.53	1.01	4.62
PBT / Share (Rs.)	3.00	1.54	1.45	0.36	0.55
Net Profit / Share (Rs.)	2.03	1.20	1.05	0.25	0.41
PBDIT Margin (%)	1.93	3.01	4.56	1.12	3.73
PBIT Margin (%)	1.64	2.79	4.43	1.07	3.70
PBT Margin (%)	1.02	0.97	1.16	0.39	0.44
Net Profit Margin (%)	0.69	0.75	0.84	0.26	0.33
Return on Networth / Equity (%)	5.27	3.29	2.98	0.73	1.22
Return on Capital Employeed (%)	11.86	9.95	12.12	1.95	8.56
Return On Assets (%)	1.50	1.49	1.09	0.26	0.42
Long Term Debt / Equity (X)	0.04	0.14	0.20	0.36	0.42
Total Debt / Equity (X)	0.56	0.68	0.74	0.96	1.07
Asset Turnover Ratio (%)	2.73	1.80	1.30	0.96	1.19
Current Ratio (X)	1.38	2.19	1.86	2.13	2.14
Quick Ratio (X)	1.26	1.11	0.96	1.06	0.85
Inventory Turnover Ratio (X)	1.54	0.53	0.07	0.23	0.00
Interest Coverage Ratio (X)	3.09	1.65	1.40	1.65	1.15
Interest Coverage Ratio (Post Tax) (X)	2.10	1.41	1.26	1.39	1.10
Enterprise Value (Cr.)	83.14	85.69	99.92	52.54	57.63
EV / Net Operating Revenue (X)	0.37	0.71	1.06	0.74	0.61
EV / EBITDA (X)	19.38	23.71	23.26	66.02	16.40
MarketCap / Net Operating Revenue (X)	0.32	0.61	0.91	0.42	0.32
Price / BV (X)	2.47	2.66	3.22	1.15	1.17
Price / Net Operating Revenue (X)	0.32	0.61	0.91	0.42	0.32
EarningsYield	0.02	0.01	0.01	0.01	0.01

After reviewing the key financial ratios for Chandra Bhagat Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 2.03. This value is below the healthy minimum of 5. It has increased from 1.20 (Mar 23) to 2.03, marking an increase of 0.83.
For Diluted EPS (Rs.), as of Mar 24, the value is 2.03. This value is below the healthy minimum of 5. It has increased from 1.20 (Mar 23) to 2.03, marking an increase of 0.83.
For Cash EPS (Rs.), as of Mar 24, the value is 2.88. This value is below the healthy minimum of 3. It has increased from 1.55 (Mar 23) to 2.88, marking an increase of 1.33.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 38.45. It has increased from 36.42 (Mar 23) to 38.45, marking an increase of 2.03.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 38.45. It has increased from 36.42 (Mar 23) to 38.45, marking an increase of 2.03.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 293.40. It has increased from 158.61 (Mar 23) to 293.40, marking an increase of 134.79.
For PBDIT / Share (Rs.), as of Mar 24, the value is 5.69. This value is within the healthy range. It has increased from 4.79 (Mar 23) to 5.69, marking an increase of 0.90.
For PBIT / Share (Rs.), as of Mar 24, the value is 4.84. This value is within the healthy range. It has increased from 4.44 (Mar 23) to 4.84, marking an increase of 0.40.
For PBT / Share (Rs.), as of Mar 24, the value is 3.00. This value is within the healthy range. It has increased from 1.54 (Mar 23) to 3.00, marking an increase of 1.46.
For Net Profit / Share (Rs.), as of Mar 24, the value is 2.03. This value is within the healthy range. It has increased from 1.20 (Mar 23) to 2.03, marking an increase of 0.83.
For PBDIT Margin (%), as of Mar 24, the value is 1.93. This value is below the healthy minimum of 10. It has decreased from 3.01 (Mar 23) to 1.93, marking a decrease of 1.08.
For PBIT Margin (%), as of Mar 24, the value is 1.64. This value is below the healthy minimum of 10. It has decreased from 2.79 (Mar 23) to 1.64, marking a decrease of 1.15.
For PBT Margin (%), as of Mar 24, the value is 1.02. This value is below the healthy minimum of 10. It has increased from 0.97 (Mar 23) to 1.02, marking an increase of 0.05.
For Net Profit Margin (%), as of Mar 24, the value is 0.69. This value is below the healthy minimum of 5. It has decreased from 0.75 (Mar 23) to 0.69, marking a decrease of 0.06.
For Return on Networth / Equity (%), as of Mar 24, the value is 5.27. This value is below the healthy minimum of 15. It has increased from 3.29 (Mar 23) to 5.27, marking an increase of 1.98.
For Return on Capital Employeed (%), as of Mar 24, the value is 11.86. This value is within the healthy range. It has increased from 9.95 (Mar 23) to 11.86, marking an increase of 1.91.
For Return On Assets (%), as of Mar 24, the value is 1.50. This value is below the healthy minimum of 5. It has increased from 1.49 (Mar 23) to 1.50, marking an increase of 0.01.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.14 (Mar 23) to 0.04, marking a decrease of 0.10.
For Total Debt / Equity (X), as of Mar 24, the value is 0.56. This value is within the healthy range. It has decreased from 0.68 (Mar 23) to 0.56, marking a decrease of 0.12.
For Asset Turnover Ratio (%), as of Mar 24, the value is 2.73. It has increased from 1.80 (Mar 23) to 2.73, marking an increase of 0.93.
For Current Ratio (X), as of Mar 24, the value is 1.38. This value is below the healthy minimum of 1.5. It has decreased from 2.19 (Mar 23) to 1.38, marking a decrease of 0.81.
For Quick Ratio (X), as of Mar 24, the value is 1.26. This value is within the healthy range. It has increased from 1.11 (Mar 23) to 1.26, marking an increase of 0.15.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.54. This value is below the healthy minimum of 4. It has increased from 0.53 (Mar 23) to 1.54, marking an increase of 1.01.
For Interest Coverage Ratio (X), as of Mar 24, the value is 3.09. This value is within the healthy range. It has increased from 1.65 (Mar 23) to 3.09, marking an increase of 1.44.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.10. This value is below the healthy minimum of 3. It has increased from 1.41 (Mar 23) to 2.10, marking an increase of 0.69.
For Enterprise Value (Cr.), as of Mar 24, the value is 83.14. It has decreased from 85.69 (Mar 23) to 83.14, marking a decrease of 2.55.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.71 (Mar 23) to 0.37, marking a decrease of 0.34.
For EV / EBITDA (X), as of Mar 24, the value is 19.38. This value exceeds the healthy maximum of 15. It has decreased from 23.71 (Mar 23) to 19.38, marking a decrease of 4.33.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.32. This value is below the healthy minimum of 1. It has decreased from 0.61 (Mar 23) to 0.32, marking a decrease of 0.29.
For Price / BV (X), as of Mar 24, the value is 2.47. This value is within the healthy range. It has decreased from 2.66 (Mar 23) to 2.47, marking a decrease of 0.19.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.32. This value is below the healthy minimum of 1. It has decreased from 0.61 (Mar 23) to 0.32, marking a decrease of 0.29.
For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 23) to 0.02, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Chandra Bhagat Pharma Ltd as of March 12, 2025 is: ₹53.84

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Chandra Bhagat Pharma Ltd is Overvalued by 16.91% compared to the current share price 64.80

Intrinsic Value of Chandra Bhagat Pharma Ltd as of March 12, 2025 is: 82.33

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Chandra Bhagat Pharma Ltd is Undervalued by 27.05% compared to the current share price 64.80

Last 5 Year EPS CAGR: 52.91%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has shown consistent growth in sales (98.77 cr) and profit (0.92 cr) over the years.	The stock has a low average ROCE of 9.75%, which may not be favorable. The stock has a high average Working Capital Days of 147.92, which may not be favorable. The stock has a high average Cash Conversion Cycle of 151.25, which may not be favorable. The company has higher borrowings (22.85) compared to reserves (12.92), which may suggest financial risk.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chandra Bhagat Pharma Ltd:
1. Net Profit Margin: 0.69%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 11.86% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 5.27% (Industry Average ROE: 16.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 2.1
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.26
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 30.9 (Industry average Stock P/E: 42.42)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.56
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Chandra Bhagat Pharma Ltd. is a Public Limited Listed company incorporated on 10/03/2003 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH2003PLC139534 and registration number is 139534. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 221.37 Cr. and Equity Capital is Rs. 7.55 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	323-F Bhagat Bhuvan, Mumbai Maharashtra 400019	compliancecbc@gmail.com http://www.cbcpharma.com

Management
Name	Position Held
Mr. Hemant Chandravadan Bhagat	Chairman & Managing Director
Mr. Pranav Hemant Bhagat	Whole Time Director
Mrs. Prachi Pranav Bhagat	Director & CFO
Mr. Ravindra Gajanan Awati	Independent Director
Ms. Abha Praveen Doshi	Independent Director

FAQ

What is the latest intrinsic value of Chandra Bhagat Pharma Ltd?

The latest intrinsic value of Chandra Bhagat Pharma Ltd as on 12 March 2025 is ₹53.84, which is 16.91% lower than the current market price of 64.80, indicating the stock is overvalued by 16.91%. The intrinsic value of Chandra Bhagat Pharma Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹48.9 Cr. and recorded a high/low of ₹124/55.4 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹22 Cr and total liabilities of ₹95 Cr.

What is the Market Cap of Chandra Bhagat Pharma Ltd?

The Market Cap of Chandra Bhagat Pharma Ltd is 48.9 Cr..

What is the current Stock Price of Chandra Bhagat Pharma Ltd as on 12 March 2025?

The current stock price of Chandra Bhagat Pharma Ltd as on 12 March 2025 is ₹64.8.

What is the High / Low of Chandra Bhagat Pharma Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Chandra Bhagat Pharma Ltd stocks is ₹124/55.4.

What is the Stock P/E of Chandra Bhagat Pharma Ltd?

The Stock P/E of Chandra Bhagat Pharma Ltd is 30.9.

What is the Book Value of Chandra Bhagat Pharma Ltd?

The Book Value of Chandra Bhagat Pharma Ltd is 39.4.

What is the Dividend Yield of Chandra Bhagat Pharma Ltd?

The Dividend Yield of Chandra Bhagat Pharma Ltd is 0.00 %.

What is the ROCE of Chandra Bhagat Pharma Ltd?

The ROCE of Chandra Bhagat Pharma Ltd is 7.95 %.

What is the ROE of Chandra Bhagat Pharma Ltd?

The ROE of Chandra Bhagat Pharma Ltd is 5.42 %.

What is the Face Value of Chandra Bhagat Pharma Ltd?

The Face Value of Chandra Bhagat Pharma Ltd is 10.0.